Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$179.10 +1.9%	$165.32	$111.09 ▼ $183.00	$10.95B	0.37	495,538 shs	377,009 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.57 million shs	N/A
NAMS NewAmsterdam Pharma	$18.40 +1.0%	$18.54	$14.06 ▼ $27.29	$2.07B	-0.03	701,037 shs	882,835 shs
ROIV Roivant Sciences	$11.54 +0.3%	$11.00	$8.73 ▼ $13.06	$7.85B	1.17	5.63 million shs	7.28 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.63%	-1.09%	+8.51%	+9.15%	+37.49%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.13%	+72.20%
NAMS NewAmsterdam Pharma	+1.39%	-7.80%	+3.41%	-22.21%	+1.05%
ROIV Roivant Sciences	+0.44%	+3.79%	+5.80%	+7.78%	+7.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	2.6448 of 5 stars	3.5	3.0	0.0	2.2	1.7	0.6
ITCI Intra-Cellular Therapies	0.9184 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
NAMS NewAmsterdam Pharma	3.0547 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0
ROIV Roivant Sciences	2.6153 of 5 stars	3.5	3.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	23.21% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	133.09% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	51.65% Upside

Current Analyst Ratings Breakdown

Latest NAMS, ITCI, ROIV, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/9/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$201.00 ➝ $216.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
6/3/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$196.00 ➝ $201.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/12/2025	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$393.54M	27.82	N/A	N/A	($1.88) per share	-95.27
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
NAMS NewAmsterdam Pharma	$45.56M	45.34	N/A	N/A	$8.20 per share	2.24
ROIV Roivant Sciences	$29.05M	270.05	N/A	N/A	$7.45 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	746.25	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest NAMS, ITCI, ROIV, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.04	0.71
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
ITCI Intra-Cellular Therapies	92.33%
NAMS NewAmsterdam Pharma	89.89%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
ITCI Intra-Cellular Therapies	2.60%
NAMS NewAmsterdam Pharma	20.84%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

NAMS, ITCI, ROIV, and ASND Headlines

Recent News About These Companies

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24 at 5:20 PM | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24 at 4:16 AM | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23 at 3:03 PM | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23 at 2:28 PM | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23 at 2:27 PM | marketbeat.com

Assenagon Asset Management S.A. Takes $570,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 20, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Earns "Buy" Rating from HC Wainwright

June 20, 2025 | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) Shares Up 5.4% - What's Next?

June 18, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)

June 18, 2025 | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, ITCI, ROIV, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$179.10 +3.32 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$178.92 -0.17 (-0.10%)

As of 05:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

NewAmsterdam Pharma NASDAQ:NAMS

$18.40 +0.19 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$18.40 0.00 (0.00%)

As of 04:38 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Roivant Sciences NASDAQ:ROIV

$11.54 +0.04 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$11.60 +0.06 (+0.48%)

As of 05:54 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time